Emerging Vaccine Technologies

Vaccines that use protein subunits or recombinant vectors are now the most common types of vaccines in development for infectious diseases and cancer, as they are relatively easy to produce and can be tailored to target specific antigens. Other types of vaccines, such as inactivated organisms, toxoids, conjugates, and genetic vaccines (mRNA, DNA), are also available, but each has its own unique development and manufacturing requirements. Rapidly shifting modalities require broad CDMO expertise and capacity.

Commercializing recombinant vector vaccines requires a skill set that differs from protein or peptide based approaches. A CDMO should be prepared to support the client’s vector selection or to suggest one from their own portfolio. FUJIFILM Diosynth Biotechnologies has broad and deep experience with virus and viral vector production, plus the analytical expertise to ensure drug product quality and potency at a range of production scales.